What company developed the world's first 'anchor technology' for endoscopic treatment devices and is based in Sendai City, Miyagi Prefecture?

KOEDA Inc., headquartered in Sendai City, Aoba Ward, Miyagi Prefecture, developed the world's first 'anchor technology' for endoscopic treatment devices targeting digestive diseases like acute cholecystitis.

Which financial institution invested in KOEDA Inc. through a third-party allotment of new shares in addition to existing investor Tohoku University Venture Partners?

Mitsubishi UFJ Capital Co., Ltd. invested in KOEDA Inc. through a third-party allotment of new shares, alongside additional funding from existing investor Tohoku University Venture Partners Co., Ltd.

What major milestone did KOEDA Inc. achieve in 2025 regarding its medical device development?

In 2025, KOEDA Inc. successfully completed First in Human (FIH) trials, demonstrating the safety of its anchor stent technology for clinical application in humans.

What are the three primary uses of the funds raised by KOEDA Inc. from Mitsubishi UFJ Capital and other investors?

The funds will be used to accelerate domestic clinical trials, strengthen regulatory and Quality Management Systems for Japan and FDA approval, and prepare for global expansion including FDA clearance and IP strategy.

What medical condition does KOEDA Inc.'s anchor stent technology aim to treat through simplified endoscopic procedures?

KOEDA Inc.'s anchor stent technology targets digestive diseases including acute cholecystitis, simplifying endoscopic procedures such as EUS-GBD and EUS-GJ drainage with reduced procedure times.

AI News NQ Analysis

KOEDA Inc., Developing Next-Generation Anchor Stents Revolutionizing Endoscopic Treatment, Raises New Funds from Mitsubishi UFJ Capital

NQ Score 91/100

AI Summary (NQ-processed)

KOEDA Inc., a developer of next-generation endoscopic treatment devices using innovative "anchor technology," has secured new funding from Mitsubishi UFJ Capital, following additional investment from Tohoku University Venture Partners. This capital will accelerate domestic clinical trials and US market entry, aiming for an M&A exit by 2030.

AI analysis data is not yet available.

Frequently Asked Questions

Q: What company developed the world's first 'anchor technology' for endoscopic treatment devices and is based in Sendai City, Miyagi Prefecture?: A: KOEDA Inc., headquartered in Sendai City, Aoba Ward, Miyagi Prefecture, developed the world's first 'anchor technology' for endoscopic treatment devices targeting digestive diseases like acute cholecystitis.
Q: Which financial institution invested in KOEDA Inc. through a third-party allotment of new shares in addition to existing investor Tohoku University Venture Partners?: A: Mitsubishi UFJ Capital Co., Ltd. invested in KOEDA Inc. through a third-party allotment of new shares, alongside additional funding from existing investor Tohoku University Venture Partners Co., Ltd.
Q: What major milestone did KOEDA Inc. achieve in 2025 regarding its medical device development?: A: In 2025, KOEDA Inc. successfully completed First in Human (FIH) trials, demonstrating the safety of its anchor stent technology for clinical application in humans.
Q: What are the three primary uses of the funds raised by KOEDA Inc. from Mitsubishi UFJ Capital and other investors?: A: The funds will be used to accelerate domestic clinical trials, strengthen regulatory and Quality Management Systems for Japan and FDA approval, and prepare for global expansion including FDA clearance and IP strategy.
Q: What medical condition does KOEDA Inc.'s anchor stent technology aim to treat through simplified endoscopic procedures?: A: KOEDA Inc.'s anchor stent technology targets digestive diseases including acute cholecystitis, simplifying endoscopic procedures such as EUS-GBD and EUS-GJ drainage with reduced procedure times.